Aarhus Universitets segl

English

Du er her: AU » Om AU » Organisation » Osteoprotegerin and mortality in hemodialysis patients wi...

Om AU

Osteoprotegerin and mortality in hemodialysis patients with cardiovascular disease

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

Standard

Osteoprotegerin and mortality in hemodialysis patients with cardiovascular disease. / Winther, Simon; Christensen, Jeppe Hagstrup; Flyvbjerg, Allan et al.
I: Clinical Nephrology, Bind 80, Nr. 3, 22.01.2013, s. 161-167.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

Harvard

Winther, S, Christensen, JH, Flyvbjerg, A, Schmidt, EB, Jørgensen, KA, Jørgensen, HS & Svensson, M 2013, 'Osteoprotegerin and mortality in hemodialysis patients with cardiovascular disease', Clinical Nephrology, bind 80, nr. 3, s. 161-167. https://doi.org/10.5414/CN107803

APA

Winther, S., Christensen, J. H., Flyvbjerg, A., Schmidt, E. B., Jørgensen, K. A., Jørgensen, H. S., & Svensson, M. (2013). Osteoprotegerin and mortality in hemodialysis patients with cardiovascular disease. Clinical Nephrology, 80(3), 161-167. https://doi.org/10.5414/CN107803

CBE

Winther S, Christensen JH, Flyvbjerg A, Schmidt EB, Jørgensen KA, Jørgensen HS, Svensson M. 2013. Osteoprotegerin and mortality in hemodialysis patients with cardiovascular disease. Clinical Nephrology. 80(3):161-167. https://doi.org/10.5414/CN107803

MLA

Winther, Simon et al. "Osteoprotegerin and mortality in hemodialysis patients with cardiovascular disease". Clinical Nephrology. 2013, 80(3). 161-167. https://doi.org/10.5414/CN107803

Vancouver

Winther S, Christensen JH, Flyvbjerg A, Schmidt EB, Jørgensen KA, Jørgensen HS et al. Osteoprotegerin and mortality in hemodialysis patients with cardiovascular disease. Clinical Nephrology. 2013 jan. 22;80(3):161-167. doi: 10.5414/CN107803

Author

Winther, Simon ; Christensen, Jeppe Hagstrup ; Flyvbjerg, Allan et al. / Osteoprotegerin and mortality in hemodialysis patients with cardiovascular disease. I: Clinical Nephrology. 2013 ; Bind 80, Nr. 3. s. 161-167.

Bibtex

@article{63a62b13d2d94f4bbbe574284b6e3126,
title = "Osteoprotegerin and mortality in hemodialysis patients with cardiovascular disease",
abstract = "AbstractBACKGROUND: Patients treated with hemodialysis (HD) have an increased mortality, mainly caused by cardiovascular disease (CVD). Osteoprotegerin (OPG) is a glycoprotein involved in the regulation of the vascular calcification process. Previous studies have demonstrated that OPG is a prognostic marker of mortality. The aim of this study was to investigate if OPG was a prognostic marker of all-cause mortality in high-risk patients with end-stage renal disease and CVD.METHODS: We prospectively followed 206 HD patients with CVD. OPG was measured at baseline and the patients were followed for 2 years or until reaching the primary endpoint, i.e., all-cause mortality.RESULTS: All-cause mortality during follow-up was 44% (90/206). High OPG was associated with increased mortality, using the first tertile as reference, with an unadjusted HR of 1.70 (CI 1.00 - 2.88) for the second tertile and HR of 1.63 (CI 0.96 - 2.78) for the third tertile. In a multivariate Cox-regression analysis age, CRP and OPG in both the second and third tertile were significantly associated with increased mortality In the unadjusted survival analysis, a test for trend of OPG yielded a p-value of 0.08; in the adjusted analyses, the p-value for trend was 0.03.CONCLUSIONS: In a high-risk population of hemodialysis patients with previously documented cardiovascular disease, a high level of OPG was an independent risk marker of all-cause mortality.",
author = "Simon Winther and Christensen, {Jeppe Hagstrup} and Allan Flyvbjerg and Schmidt, {Erik Berg} and J{\o}rgensen, {Kaj Anker} and J{\o}rgensen, {Hanne Skou} and My Svensson",
year = "2013",
month = jan,
day = "22",
doi = "10.5414/CN107803",
language = "English",
volume = "80",
pages = "161--167",
journal = "Clinical Nephrology",
issn = "0301-0430",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "3",

}

RIS

TY - JOUR

T1 - Osteoprotegerin and mortality in hemodialysis patients with cardiovascular disease

AU - Winther, Simon

AU - Christensen, Jeppe Hagstrup

AU - Flyvbjerg, Allan

AU - Schmidt, Erik Berg

AU - Jørgensen, Kaj Anker

AU - Jørgensen, Hanne Skou

AU - Svensson, My

PY - 2013/1/22

Y1 - 2013/1/22

N2 - AbstractBACKGROUND: Patients treated with hemodialysis (HD) have an increased mortality, mainly caused by cardiovascular disease (CVD). Osteoprotegerin (OPG) is a glycoprotein involved in the regulation of the vascular calcification process. Previous studies have demonstrated that OPG is a prognostic marker of mortality. The aim of this study was to investigate if OPG was a prognostic marker of all-cause mortality in high-risk patients with end-stage renal disease and CVD.METHODS: We prospectively followed 206 HD patients with CVD. OPG was measured at baseline and the patients were followed for 2 years or until reaching the primary endpoint, i.e., all-cause mortality.RESULTS: All-cause mortality during follow-up was 44% (90/206). High OPG was associated with increased mortality, using the first tertile as reference, with an unadjusted HR of 1.70 (CI 1.00 - 2.88) for the second tertile and HR of 1.63 (CI 0.96 - 2.78) for the third tertile. In a multivariate Cox-regression analysis age, CRP and OPG in both the second and third tertile were significantly associated with increased mortality In the unadjusted survival analysis, a test for trend of OPG yielded a p-value of 0.08; in the adjusted analyses, the p-value for trend was 0.03.CONCLUSIONS: In a high-risk population of hemodialysis patients with previously documented cardiovascular disease, a high level of OPG was an independent risk marker of all-cause mortality.

AB - AbstractBACKGROUND: Patients treated with hemodialysis (HD) have an increased mortality, mainly caused by cardiovascular disease (CVD). Osteoprotegerin (OPG) is a glycoprotein involved in the regulation of the vascular calcification process. Previous studies have demonstrated that OPG is a prognostic marker of mortality. The aim of this study was to investigate if OPG was a prognostic marker of all-cause mortality in high-risk patients with end-stage renal disease and CVD.METHODS: We prospectively followed 206 HD patients with CVD. OPG was measured at baseline and the patients were followed for 2 years or until reaching the primary endpoint, i.e., all-cause mortality.RESULTS: All-cause mortality during follow-up was 44% (90/206). High OPG was associated with increased mortality, using the first tertile as reference, with an unadjusted HR of 1.70 (CI 1.00 - 2.88) for the second tertile and HR of 1.63 (CI 0.96 - 2.78) for the third tertile. In a multivariate Cox-regression analysis age, CRP and OPG in both the second and third tertile were significantly associated with increased mortality In the unadjusted survival analysis, a test for trend of OPG yielded a p-value of 0.08; in the adjusted analyses, the p-value for trend was 0.03.CONCLUSIONS: In a high-risk population of hemodialysis patients with previously documented cardiovascular disease, a high level of OPG was an independent risk marker of all-cause mortality.

U2 - 10.5414/CN107803

DO - 10.5414/CN107803

M3 - Journal article

C2 - 23547804

VL - 80

SP - 161

EP - 167

JO - Clinical Nephrology

JF - Clinical Nephrology

SN - 0301-0430

IS - 3

ER -